N-({[3,5-bis(Trifluoromethyl)phenyl]amino}carbonyl)(1-methylindol-6-yl) carboxamide | 471931-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-({[3,5-bis(Trifluoromethyl)phenyl]amino}carbonyl)(1-methylindol-6-yl) carboxamide
• 英文别名: N-[[3,5-bis(trifluoromethyl)phenyl]carbamoyl]-1-methylindole-6-carboxamide
• CAS: 471931-62-1
• 化学式: C₁₉H₁₃F₆N₃O₂
• 分子量: 429.322
• InChiKey: GVLYWTRUZWMKCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  30
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  63.1
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Antagonists of MCP-1 function and methods of use thereof
  申请人：——

  公开号：US20030092728A1

  公开（公告）日：2003-05-15

  Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Orohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.

  以下是您请求的翻译结果： 对单核细胞趋化蛋白-1（MCP-1）功能具有拮抗作用的化学化合物，包含这些化合物的药物组合物，使用这些化合物和组合物进行治疗的方法，以及制备这些化合物的方法。这些化合物可用于预防或治疗慢性或急性炎症或自身免疫性疾病，尤其是那些与异常淋巴细胞或单核细胞积聚相关的疾病，如关节炎、哮喘、动脉粥样硬化、糖尿病肾病、炎症性肠病、克罗恩病、多发性硬化症、肾炎、胰腺炎、肺纤维化、银屑病、再狭窄和移植排斥。
• ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF
  申请人：TELIK, INC.

  公开号：EP1383757A1

  公开（公告）日：2004-01-28
• US6677365B2
  申请人：——

  公开号：US6677365B2

  公开（公告）日：2004-01-13
• US6998407B2
  申请人：——

  公开号：US6998407B2

  公开（公告）日：2006-02-14
• [EN] ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF<br/>[FR] ANTAGONISTES DE LA FONCTION MCP-1 ET LEURS PROCEDES D'UTILISATION
  申请人：TELIK INC

  公开号：WO2002081463A1

  公开（公告）日：2002-10-17

  The present invention relates to chemical compounds Ia, IIa and IIIa, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.